Purpose: To investigate the expression of rapamycin target protein (mTOR) mRNA and transferrin receptor 1(Tfr1) mRNA in mucoepidermoid carcinoma of parotid gland and its relationship with prognosis.
Methods: From June 2013 to July 2015 in Tangshan Workers' Hospital, 35 patients with mucoepidermoid carcinoma of parotid gland were selected. The relative expression of mTOR and Tfr1 mRNA in mucoepidermoid carcinoma of parotid gland was detected. The relationship between mTOR mRNA, Tfr1 mRNA and the clinicopathology and prognosis of mucoepidermoid carcinoma of parotid gland was analyzed using SPSS19.0 software package.
Results: The relative expression levels of mTOR mRNA and Tfr1 mRNA in mucoepidermoid carcinoma of parotid gland were significantly higher than those in adjacent tissues(P<0.05). The relative expression of mTOR mRNA and Tfr1 mRNA was correlated with invasion depth, tumor grade, TNM stage and cervical lymphatic metastasis(P<0.05). The relative expressions of mTOR and Tfr1 in patients with good prognosis were significantly lower than those in patients with poor prognosis (P<0.05). The AUC of mTOR mRNA was 0.815, higher than that of Tfr1 mRNA(0.813). The AUC of mTOR mRNA combined with Tfr1 mRNA was 0.922, higher than that of mTOR mRNA and Tfr1 mRNA alone. Cox univariate and multivariate analysis showed that differentiation, TNM stage, mTOR mRNA and Tfr1 mRNA were closely related to poor prognosis of mucoepidermoid carcinoma of parotid gland.
Conclusions: The relative expression of mTOR mRNA and Tfr1 mRNA in patients with mucoepidermoid carcinoma of parotid gland was significantly increased, which can be used to evaluate the prognosis of patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Aurora kinase A expression in pleomorphic adenoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma of salivary glands: an immunohistochemical study.
BMC Oral Health
January 2025
Department of Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
Background: Aurora kinase A (AurkA) plays a vital role in mitosis and is therefore critical in tumors development and progression. There are a few studies on AurkA expression in salivary gland tumors. The aim of the present study was to evaluate the expression pattern of AurkA in the most common benign and malignant salivary gland tumors by immunohistochemistry.
View Article and Find Full Text PDFMalignant Salivary Gland Tumors in a Tertiary University Hospital in Northern Spain.
J Clin Med
December 2024
Radiation Oncology Department, Osakidetza, Donostia University Hospital, 20014 San Sebastian, Spain.
(1) : Salivary gland tumors (SGTs) are a rare and diverse group of neoplasms arising in the parotid, submandibular, sublingual, and minor salivary glands distributed throughout the upper aerodigestive tract. Given the rarity and complexity of MSGTs, understanding their epidemiology across diverse populations is crucial for improving diagnostic and therapeutic strategies. (2) : A retrospective analysis involving 45 patients diagnosed with malignant salivary gland tumors and treated with curative intention between 1 July 2016 and 1 July 2021 in a tertiary academic hospital was performed.
View Article and Find Full Text PDFSystematic identification of pathological mechanisms, prognostic biomarkers and therapeutic targets by integrating lncRNA expression variation in salivary gland mucoepidermoid carcinoma.
Sci Rep
January 2025
Department of Oral and Maxillofacial Surgery, National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices& Beijing Key Laboratory of Digital Stomatology & NHC Key Laboratory of Digital Stomatology & NMPA Key Laboratory for Dental Materials, Peking University School and Hospital of Stomatology, Beijing, China.
Biological processes intricately intertwine with tumorigenesis, significantly influencing treatment outcomes and prognosis. However, the mechanisms fostering mucoepidermoid carcinoma (MEC) remain inadequately elucidated. This research utilizes expression profiles of lncRNAs from clinical MEC tissues and matched normal glandular tissues, integrating public data to explore the biological mechanisms and immune microenvironment characteristics of tumorigenesis.
View Article and Find Full Text PDFAndrogen receptor overexpression by immunohistochemistry in malignant salivary gland tumors in Tanzania.
BMC Cancer
January 2025
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Background: Malignant salivary gland tumors (SGTs) present diagnostic challenges and limited treatment options. This study aims to determine the proportion of malignant SGTs overexpressing the androgen receptor (AR) by immunohistochemistry (IHC) and its association to age, sex, anatomical site, histopathological subtype and grade which may inform customized treatment approaches.
Methodology: This was a retrospective cross-sectional analytical study of archived paraffin embedded tissue blocks of malignant SGTs diagnosed at MNH Central Pathology Laboratory (CPL) from January 2019 to December 2022.
The role of irisin and cytokines in the etiology of parotid tumors.
Biotech Histochem
January 2025
Department of Ear Nose and Throat, Firat University Faculty of Medicine, Elazig, Turkey.
This study explores the role of irisin and interleukins in parotid tumors by determining the tissue staining intensity of irisin, the salivary and plasma levels of irisin, and the plasma levels of IL-4, IL-6, IL-10 and TNF-alpha in individuals with parotid tumors. Forty-eight patients and forty healthy individuals were included to the study and allocated into four group. Benign Group I (pleomorphic adenoma), Group II (Warthin's tumor), Group III (mucoepidermoid carcinoma) and Group IV (benign parotid control group, healthy control group).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!